SCHEMBL14829604

SCHEMBL14829604

O=C(c1ccc2nccnc2c1)c1cccc(O)c1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 3/20 0.49
HSD17B2 P37059 3/20 0.49
HSD17B14 Q9BPX1 3/20 0.47
MAPT P10636 4/20 0.44
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
POLB P06746 2/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
NPC1 O15118 5/20 0.42
RAB9A P51151 4/20 0.42
HPGD P15428 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14829478 0.85 NPC1 (0.48) HSD17B1HSD17B2MAPTALDH1A1MEN1
SCHEMBL14830198 0.84 NPC1 (0.46) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL14829917 0.82 NPC1 (0.44) HSD17B14MAPTALDH1A1MEN1KMT2A
SCHEMBL14829698 0.80 HPGD (0.54) HSD17B1HSD17B2HSD17B14MEN1KMT2A
SCHEMBL14829639 0.78 HSD17B1 (0.45) HSD17B1HSD17B2HSD17B14MAPTALDH1A1
SCHEMBL27293915 0.77 MAPT (0.56) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL14830113 0.77 HSD17B1 (0.50) HSD17B1HSD17B2HSD17B14MAPTALDH1A1
SCHEMBL14830197 0.76 MRGPRX4 (0.46) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL14829710 0.75 MEN1 (0.46) HSD17B1HSD17B2HSD17B14MAPTALDH1A1
SCHEMBL14830145 0.75 HPGD (0.45) ALDH1A1MEN1KMT2AHPGDHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9249111-B2 Substituted quinoxalines as B-RAF kinase inhibitors NEUPHARMA, INC. (US) 2016-02-02 US claimed
US-20140343068-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2014-11-20 US claimed
WO-2013049701-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2013-04-04 WO claimed
US-20170050938-A1 SUBSTITUTED QUINOXALINES AS B-RAF KINASE INHIBITORS NEUPHARMA, INC. 2017-02-23 US disclosed
US-9249111-B2 Substituted quinoxalines as B-RAF kinase inhibitors NEUPHARMA, INC. (US) 2016-02-02 US disclosed
US-20140343068-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2014-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343068-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS BRAF, NRAS, RAF1 HSD17B1 2306/4885HSD17B2 2582/4885HSD17B14 265/4885
US-20170050938-A1 SUBSTITUTED QUINOXALINES AS B-RAF KINASE INHIBITORS BRAF, RAF1, ARAF HSD17B1 4455/4885HSD17B2 4459/4885HSD17B14 1859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.